...
机译:资源有限或资源丰富地区的曲妥珠单抗使用的差异及其对HER2阳性乳腺癌的生存效益:来自中国的真实研究
The 307 Hospital of Chinese People's Liberation Army Department of Breast CancerBeijing People's;
Sun Yat‐sen University Cancer Center Department of Breast CancerGuangzhou People's Republic of;
Shandong Cancer Hospital Department of Breast Cancer CenterJinan People's Republic of China;
Zhejiang Cancer Hospital Department of Breast CancerHangzhou People's Republic of China;
Affiliated Hospital of Medical College Qingdao University Department of Breast Cancer;
Jiangsu Cancer Hospital Department of Breast CancerNanjing People's Republic of China;
Tumor Hospital of Harbin Medical University Department of Breast CancerHarbin People's Republic of;
Liaoning Cancer Hospital Department of Breast CancerShenyang People's Republic of China;
Hunan Cancer Hospital Department of Breast CancerChangsha People's Republic of China;
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital Department of;
Peking University First Hospital Department of Breast Cancer CenterBeijing People's Republic of;
Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital Department;
Henan Cancer Hospital Department of Breast CancerZhengzhou People's Republic of China;
The 307 Hospital of Chinese People's Liberation Army Department of Breast CancerBeijing People's;
Human epidermal growth receptor 2 positive breast cancer; Medical resource disparity; Real‐world research; Survival;
机译:资源有限或资源丰富地区的曲妥珠单抗使用的差异及其对HER2阳性乳腺癌的生存效益:来自中国的真实研究
机译:在资源有限或丰富的地区使用曲妥珠单抗的差异及其对HER2阳性乳腺癌的生存效益:来自中国的真实世界研究
机译:曲妥珠单抗在资源有限或资源丰富地区的使用差异及其对HER2阳性乳腺癌的生存获益:来自中国的世界研究
机译:HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关:回顾性和多中心研究
机译:Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
机译:曲妥珠单抗在资源有限或资源丰富地区的使用差异及其对HER2阳性乳腺癌的生存获益:来自中国的一项现实世界研究
机译:Trastuzumab加上人表皮生长因子受体2(HER2) - 阳性早期乳腺癌的辅助化学疗法:中国患者的真实回顾性研究
机译:对接受曲妥珠单抗单一疗法的IIIB和IV期HER2阳性乳腺癌患者施用HER-2 / neu(HER2)细胞内结构域(ICD)基于肽的疫苗的II期研究;年度报告。 2007年4月27日至2008年4月26日